Mantle-cell lymphoma: a population-based clinical study.

Velders, Gerjo A.; Kluin-Nelemans, Hanneke C.; Boer, Carla J. de; Hermans, Jos; Noordijk, E.M.; Schuuring, Ed; Krámer, M; Deijk, W. A. Van; Rahder, J B; Kluin, Philippus; Krieken, J H Van

doi:10.1200/jco.1996.14.4.1269

Cited by 169 publications

(98 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is concordant with previous studies indicating that proliferation is one of the best prognosis parameters in MCL. 35,37 The relationship between survivin expression, proliferation, and survival in other human tumors has not been explored. Recently, it has been described that in CLL cells, survivin is the only IAP whose expression is induced by CD40L, suggesting a role of survivin in the control of CLL proliferative pool interfacing apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival

Martı́nez

Bellosillo

Bosch

et al. 2004

The American Journal of Pathology

View full text Add to dashboard Cite

Survivin is a member of the inhibitor of apoptosis protein family that is expressed inMantle cell lymphoma (MCL) is a malignant lymphoproliferative disorder characterized by the proliferation of CD5ϩ, CD23-monoclonal B cells containing the chromosomal translocation t(11;14)(q13;q32) which places the cyclin D1 gene under the transcriptional control of the immunoglobulin heavy chain enhancer elements.

show abstract

Section: Discussionmentioning

confidence: 99%

Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival

Martı́nez

Bellosillo

Bosch

et al. 2004

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…The clinical course of MCL, although heterogeneous, is usually poor, with a survival time of 3 -4 years. For several years a high proliferation rate, as measured by counting the number of mitotic figures or of Ki-67-expressing cells, has been recognised as a marker of poor prognosis (Lardelli et al, 1990;Velders et al, 1996;Raty et al, 2002). However, due to the lack of data from prospective trials and the limited predictive power of the markers available so far, cell proliferation has rarely been used for clinical decisionmaking in MCL.…”

mentioning

confidence: 99%

Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma

et al. 2005

View full text Add to dashboard Cite

Minichromosome maintenance protein 6 (MCM6) is one of six proteins of the MCM family which are involved in the initiation of DNA replication and thus represent a marker of proliferating cells. Since the level of cell proliferation is the most valuable predictor of survival in mantle cell lymphoma (MCL), we investigated lymph node biopsy specimens from 70 patients immunohistochemically with a monoclonal antibody against MCM6. The percentage of MCM6 expressing lymphoma cells ranged from 12.0 to 95.6%, with a mean of 61.0%, and was significantly higher than the percentage of Ki-67-positive cells (Po0.0001). Surprisingly, the ratio of MCM6-positive cells to Ki-67-positive cells was higher than in normal stimulated peripheral blood mononuclear cells, indicating a cell early G1-phase arrest in MCL. A high MCM6 expression level of more than 75% positive cells was associated with a significantly shorter overall survival time (16 months) compared to MCL with a low MCM6 expression level of less than 25% (no median reached, Po0.0001). Multivariate analysis revealed MCM6 to be an independent predictor of survival that is superior to the international prognostic factor and the Ki-67 index. Therefore, aside from gene expression profiling, immunohistochemical detection of MCM6 seems to be the most promising marker for predicting the outcome in MCL.

show abstract

“…1,2 Unlike other aggressive nonHodgkin lymphoma (NHL), patients with MCL have a poorer complete response rate with standard anthracyclinebased or non-anthracycline-based regimens. 3,4 High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is an effective form of treatment for relapsed NHL.…”

Section: Introductionmentioning

confidence: 99%

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Joao

Porrata

Inwards

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is an effective treatment strategy for mantle-cell lymphoma (MCL) demonstrating significantly prolonged progression-free survival (PFS) when compared to interferon-a maintenance therapy of patients in first remission. The study of absolute lymphocyte count at day 15 (ALC-15) after ASCT as a prognostic factor in non-Hodgkin lymphoma (NHL) included different lymphoma subtypes. The relationship of ALC-15 after ASCT in MCL has not been specifically addressed. We evaluated the impact of ALC-15 recovery on survival of MCL patients undergoing ASCT. We studied 42 consecutive MCL patients who underwent ASCT at the Mayo Clinic in Rochester from 1993 to 2005. ALC-15 threshold was set at 500 cells/ll. The median follow-up after ASCT was 25 months (range, 2-106 months). The median overall survival (OS) and PFS times were significantly better for the 24 patients who achieved an ALC-15 X500 cells/ll compared with 18 patients with ALC-15 o500 cells/ll (not reached vs 30 months, Po0.01 and not reached vs 16 months, Po0.0006, respectively). Multivariate analysis demonstrated ALC-15 to be an independent prognostic factor for OS and PFS. The ALC-15 X500 cells/ll is associated with a significantly improved clinical outcome following ASCT in MCL.

show abstract

Mantle-cell lymphoma: a population-based clinical study.

Abstract: MCL is a disease of the elderly, who present with widespread disease and with a poor response to therapy. Although it harbors features of an indolent NHL, it behaves clinically as an aggressive NHL with a short overall survival time.

Cited by 169 publications

References 16 publications

Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival

Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival

Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Contact Info

Product

Resources

About